Evidence map›Paper›PMID 41136829›Full record

ReviewAdvances in experimental medicine and biology2025

Standardization of Stem Cell and Regenerative Medicine in China.

Jiani Cao, Jun Wei, Ranran Xu, Glyn N Stacey, Jie Hao, Hongling Zhao, Baoyang Hu, Qi Zhou, Yu Alex Zhang, Tongbiao Zhao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiani CaoState Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Jun WeiBeijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.
Ranran XuZephyrm Biotechnologies, Beijing, China.
Glyn N StaceyInternational Stem Cell Biobanking Initiative, Barley, Hertfordshire, UK.
Jie HaoState Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Hongling ZhaoState Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Baoyang Hu *State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Qi Zhou *State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Yu Alex Zhang *Zephyrm Biotechnologies, Beijing, China.
Tongbiao Zhao *Institute of Zoology, Chinese Academy of Sciences, Beijing, China. tbzhao@ioz.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cells hold tremendous promise for regenerative medicine. With continuous development in this field, stem cell medicines are starting to enter mainstream drug development. Due to their distinct and complex characteristics, which are significantly different from those of traditional medicine, new opportunities and challenges are arising in stem cell medicine development. Therefore, to facilitate the clinical translation of stem cells and adapt to scientific and technological progress, it is important to formulate and update regulatory policies and standards that are specifically appropriate for cell therapy. In this section, we discuss the regulatory policies on stem cell medicine and drug standards in China, and review the ongoing development of international and Chinese standards related to stem cell medicine. Finally, we discuss the framework for establishing a standard system for stem cell medicine in the future.

Indexed as

Regenerative MedicineStem CellsStem Cell TransplantationAnimalsChinaHumansCell therapyRegenerative medicineRegulatory policiesStandardStem cell

Identifiers

PMID41136829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.